asia pacific peptide therapeutics Market

The Asia Pacific peptide therapeutics market is expected to reach US$ 10,565.67 million by 2027 from US$ 4,986.73 million in 2019; it is estimated to grow at a CAGR of 9.9% from 2020 to 2027. The growth of the Asia Pacific peptide therapeutics market is attributed to key driving factors, such as growing investments in peptide therapeutics and increasing prevalence of metabolic disorders and infectious diseases. However, operational limitations of peptides are expected to restrain the growth of the market during the forecast period.

Peptides are naturally occurring biological molecules that play a prominent role in important biological activities. Continuous R&D activities in peptide therapeutics have discovered its benefits in tackling a range of chronic disorders, such as renal disorders, genetic conditions, oncology, and neurodegenerative conditions. Over 7,000 naturally occurring peptides have been identified in recent years, which have crucial roles in human physiology, including actions as neurotransmitters, hormones, ion channel ligands, and growth factors. The effectiveness of the outcomes of peptide therapies is generating investments in the development of new drugs. Also, increasing prevalence of metabolic and infectious diseases is one of the prominent factors expected to drive the peptide therapeutics market. An estimated 1.2 million Australians (4.9% of the total population) were suffering from diabetes in 2018, based on self-reported data from the Australian Bureau of Statistics. Hence, increase in investments in the development of new drugs for peptide therapies and applicability of therapies for treatment of viral infections and chronic diseases are expected to accelerate the growth of the peptide therapeutics market during the forecast period.

The outbreak of the COVID-19 pandemic has extensively affected the countries in the Asia Pacific region. However, growing research on peptide therapies to treat COVID-19 patients is likely to favor the market growth. For instance, in September 2020, a research study called “The Potential of Antiviral Peptides as COVID-19 Therapeutics” was conducted at the University of Nottingham, Malaysia. Thus, growing research on peptide therapies is expected to positively impact the peptide therapeutics market during the forecast period.

Based on type, the Asia Pacific peptide therapeutics market is segmented into generic and innovative. The innovative segment held the largest share of the market in 2019, whereas the generic segment is anticipated to register the highest CAGR in the market during the forecast period.

In terms of route of administration, the Asia Pacific peptide therapeutics market is categorized into parenteral, oral, mucosal, pulmonary, and others. The parenteral segment held the largest share of the market in 2019; however, the oral segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on synthesis technology, the Asia Pacific peptide therapeutics market is segmented into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid technology. The solid phase peptide synthesis segment held the largest share of the market in 2019. The hybrid technology segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on application, the Asia Pacific peptide therapeutics market is categorized into cancer, cardiovascular disorder, metabolic disorder, respiratory disorder, pain, and dermatology. The cancer segment held the largest share of the market in 2019. However, the metabolic disorder segment is estimated to register the highest CAGR in the market during the forecast period.

Primary and secondary sources associated with this report on the Asia Pacific peptide therapeutics market include Centers for Disease Control and Prevention (CDC), Japanese Society of Molecular Cell Biology of Macrophages, (MMCB) and International Diabetes Federation (IDF).